Leukemia

DF/肝细胞癌白血病计划继续侧重于促进对分子的理解 发病机制是定义新的通路和蛋白质靶点的一种手段，可以抑制这些途径和蛋白质靶点来改善 急性白血病、骨髓增生异常综合征和骨髓增生性肿瘤患者的预后。这个 该计划的长期目标是加速将新发现从实验室转化为 临床，首先进入动物模型的临床前试验，然后进入创新的、研究人员发起的I或11阶段 临床试验。该计划的具体目标是：1)确定新的细胞和分子机制， 有助于白血病和相关疾病的发病机制；2)建立准确的动物模型 提高对白血病发病机制的认识，开发有针对性的抗白血病药物；以及3) 设计和实施临床试验，将白血病内的实验室研究发现转化为 计划和癌症中心作为一个整体。 白血病计划自2000年以来一直由CCSG资助。该计划获得了突出的优异成绩 在2005年的上一次竞争性审查时。60名计划成员代表以下四个部门 HMS、HSPH的一个部门和六个DF/CC成员机构。该计划将继续 资金充足，有3560万美元的同行审查资金，其中1600万美元来自NCI，196万美元 100万美元是其他同行评审的资金(2009年，总成本)。计划成员中有879人与计划相关 2006年至2010年的出版物。其中16%是计划内交互，43%是 方案间的和机构间的占27%。

The DF/HCC Leukemia Program continues to focus on advancing the understanding of molecular pathogenesis as a means to define novel pathways and protein targets that can be inhibited to improve the outcome of patients with acute leukemias, myelodysplastic syndromes and myeloproliferative neoplasms. The long-range goal of the Program is to accelerate the translation of novel discoveries from the laboratory to the clinic, first into preclinical testing in animal models and then into innovative, investigator-initiated Phase I or 11 clinical trials. The Program's Specific Aims are: 1) to identify novel cellular and molecular mechanisms that contribute to the pathogenesis of leukemia and related diseases; 2) to generate accurate animal models of leukemia to improve the understanding of pathogenesis and to develop targeted anti-leukemic agents; and 3) to design and implement clinical trials to translate laboratory research discoveries made within the Leukemia Program and the Cancer Center as a whole. The Leukemia Program has been CCSG funded since 2000. The Program received an outstanding merit score at the time of the last competitive review in 2005. The 60 Program members represent four departments of HMS, one department of HSPH and six DF/HCC member institutions. The Program continues to be well-funded with $35.6 million in peer-reviewed funding, of which $16 million was from the NCI and $19.6 million was other peer reviewed funding (2009, total costs). Program members had 879 in Program-relevant publications from 2006 through 2010. Of these 16% were intra-programmatic interactions, 43% were inter-programmatic and 27% were inter-institutional.